Competitive ELISA, Immobilized antigen
The Rat-MID™ Osteocalcin EIA is an enzyme-linked immunosorbent assay for the quantitative determination of osteocalcin in rat serum and plasma. The assay is for research use only. The clinical utility of rat osteocalcin as a marker for bone turnover has been evaluated in several preclinical settings. It has been reported that the serum level increases after ovariectomy and this oestrogen deficiency-induced state can be prevented by treatment with either oestrogen, selective oestrogen receptor modulators (SERMs) or bisphosphonates.
Osteocalcin or bone Gla protein (BGP) is a major non-collagenous protein of the bone matrix. It has a molecular weight of approximately 6000 Dalton and consists in most species of 49 amino acids; however, rat osteocalcin consists of 50 amino acids. Osteocalcin has a unique property for binding to calcium facilitated by the presence of 2-3 gamma-carboxyglutamic acids at position 17, 21 and 24. The mid-molecular part of osteocalcin, especially the amino acids between 20 and 30, exhibits a high degree of inter-species conservation. The Rat-MID™ Osteocalcin EIA is based upon the competitive binding of a monoclonal antibody to soluble osteocalcin or to immobilised osteocalcin. Briefly, the monoclonal antibody is raised against human osteocalcin and recognizes the mid-molecular part (amino acids 21-29) of the molecule.
Store the complete kit at 2–8°C. Under these conditions, the kit is stable until the expiration date (see label on the box).
Limit of Detection